Dario Eklund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

United statesUnited kingdomSwitzerland generalShabir hashamDario eklundAndrew smithEva kaliasChiesi farmaceuticiAmerica to catalyst pharmaceuticals incLife science allianceNational institute for healthSanthera pharmaceuticals holdingCatalyst pharmaceuticals incExchange regulation ltdRegulatory agencySanthera pharmaceuticals holding ltd

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDennis riedlEva kaliasDario eklundShabir hashamChiesi farmaceuticiAndrew smithSanthera pharmaceuticalsChina national medical products administrationCatalyst pharmaceuticalsHead investor relations communicationsExchange regulationEuropean medicines agencyEuropean union summary of product characteristics

Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDario eklundEva kaliasSilvia hornkampEuropean commissionGerman duchenne foundationLife science allianceEuropean unionSanthera pharmaceuticals holdingAmerica to catalyst pharmaceuticalsHead investor relations communicationsDrug administrationRegulatory agencyEuropean medicines agency

EC approves Santhera s Duchenne muscular dystrophy drug Agamree

EC approves Santhera s Duchenne muscular dystrophy drug Agamree
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesDario eklundDrug administrationEuropean medicines agencyEuropean commissionAmerica to catalyst pharmaceuticalsSanthera pharmaceutical agamreeNorth americaCatalyst pharmaceuticals

Santhera s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Santhera’s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

United kingdomSwitzerland generalUnited statesElizabeth vroomDario eklundCatalyst pharmaceuticalsWorld duchenne organizationCommittee for medicinal products human useEuropean commissionLife science allianceAmerica to catalyst pharmaceuticalsRegulatory agencyEuropean unionSanthera pharmaceuticalsEnergyx ray absorptiometryEuropean medicines agency